Category: Pharma & Biotech

Abattis Rebrands as a Downstream Solutions Provider for the Cannabis Market

SHARE THIS POST VANCOUVER, BRITISH COLUMBIA / March 6, 2018 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT / OTC: ATTBF) is pleased to announce it has officially rebranded itself as a one-stop provider of downstream cannabis solutions for licensed producers (“LPs”) and manufacturers of cannabinoid-containing products. The Company’s new focus on downstream solutions reflects several of its recent acquisitions and the success of its fully integrated services offerings. These offerings now include biomass production, federally-licensed research and development and analytical services, regulatory services, logistics support for the manufacture, sale, distribution and marketing of cannabinoid-containing finished products and cannabinoid delivery products and blockchain-based peer-to-peer payment technologies. “We intend for the rebranding to consolidate our recent acquisitions and pave the way for exciting new partnerships in the future”, stated Rob Abenante, President and CEO of Abattis. “For example, our recent acquisition of Gabriola Green Farms will round out our supply chain, providing us and our partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts,” added Mr. Abenante. “While continuing to develop our in-house nanotechnology delivery platforms, we hope to support our partners in multiple aspects of their businesses, from helping them increase manufacturing and distribution capacity to, in the case of established brands, guiding their entry into the cannabis space. Our suite of integrated services will also address our partners’ future needs,...

Read More

Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing

SHARE THIS POST Company Expects to Initiate Pivotal Study Mid-Year 2018 and Deliver Top-line Data in 2019 Devon, PA, March 5, 2018 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the results of a positive meeting held with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a patent-protected permeation-enhanced transdermal gel. Zynerba has received U.S. Orphan Drug designation for the use of CBD as a treatment of FXS. Currently, there are no approved therapies to treat FXS or its most common symptoms. Based on the Company’s dialogue with the FDA, the Company expects to initiate a single pivotal study mid-year 2018 to support a New Drug Application (NDA) for ZYN002 in FXS. The FDA and the Company are in agreement that the primary and key secondary endpoints for the study should assess observable behaviors in patients with FXS as reported by the caregiver using the validated Aberrant Behavior Checklist in Fragile X syndrome (ABC-FXS). If the pivotal...

Read More

Tetra Bio-Pharma Announces Closing of Bought Deal Financing

SHARE THIS POST OTTAWA, March 05, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX-V:TBP) (OTCQB:TBPMF), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option. A total of 11,500,000 units (the “Units”) of the Corporation were sold at a price of $1.00 per Unit, for aggregate gross proceeds of $11,500,00 (the “Offering”). Each Unit consisted of one common share of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one common share of the Corporation at a price of $1.30 until March 5, 2021. The Offering was underwritten by Echelon Wealth Partners Inc. The Corporation intends to use the net proceeds from the Offering to continue the development of its clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers, to repay indebtedness of the Corporation, and for working capital and general corporate purposes. “We are extremely pleased to have worked with Echelon Wealth Partners in this financing . As we are about to initiate our Health Canada approved phase 3 registration trial for our lead drug candidate, PPP001, for late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and potentially accelerate some of the key development projects in our...

Read More

Cannabis Science Integrates iCannabinoid Into Pharmacy Openings, While Building, Product Manufacturing, Packaging & Cultivation Procedures are Pending CBIS and City Approvals

SHARE THIS POST Grand Opening of First CBIS Pharmacies Expected Soon IRVINE, CA, March 05, 2018 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company’s first two PRE-ICO, medical marijuana-based pharmacies are currently undergoing building inspections, and the Company is conducting final tests on all systems from inventory through final sale. Additionally, CBIS is planning the integration of iCannabinoid, the Company’s state-of-the-art social media and educational interactive online platform into the CBIS Pharmacy openings. “The buildouts are pretty much done, and these stores are beautiful, touch-screen, state-of-the-art facilities,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “The Company management should be proud, as we will soon conduct pre-opening, live testing of an interactive set of iCannabinoid My Health Modules that will enable users to track personal health goals and milestones, and many other items relating to personal health maintenance. There will also be medical, action-tracking support Action Groups for heart monitoring, pain monitoring, eating, sleep monitoring, exercise monitoring, and many more groups that can be created and customized to fit the personal needs of users.” As we prepare to open our first CBIS-Branded Pharmacies, plans are well underway for the development of the much-anticipated, CBIS Manufacturing and Distribution Complex. CBIS’ quality assurance program will also be applied to the development and...

Read More

INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Infantile Spasms

SHARE THIS POST PHOENIX, March 02, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the initiation of a Phase 3 clinical trial to study cannabidiol (CBD) oral solution for the treatment of infantile spasms, a rare type of pediatric epilepsy that occurs in very young children, with the first trial site’s activation. “We need better treatments for infantile spasms, one of the more severe and dangerous seizure disorders of early childhood,” said Shaun Hussain, M.D., a pediatric neurologist at UCLA Mattel Children’s Hospital and director of its Infantile Spasms Project. “That’s why we’re excited about this pivotal study, which has the potential to reveal a new piece of the treatment puzzle for infantile spasms.”In previous studies, CBD—one of the main molecules in cannabis—has demonstrated sustained clinical benefits in a variety of medically refractory pediatric epilepsies, including infantile spasms, an uncommon condition estimated by the Child Neurology Foundation (CNF) to be diagnosed in about 1,200 children in the United States each year. “We have great hope in the potential of our proprietary formulation of pharmaceutical-grade, synthetically manufactured CBD oral solution in combination with vigabatrin to offer greater seizure control to children with infantile spasms,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “The need for more efficacious and better tolerated...

Read More

India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)

SHARE THIS POST BETHESDA, Md., March 01, 2018 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American:IGC) today announces that it has signed a Joint Development and Services Agreement with the prestigious Parkinson’s Institute and Clinical Center of Sunnyvale, California. The Parkinson’s Institute and Clinical Center will work with IGC in identifying new clinical end points for Parkinson’s disease and movement disorders that could be used to determine if natural products can help with the debilitating symptoms in Parkinson’s patients. The Parkinson’s Institute and Clinical Center will assist in designing trials and creating protocols including a schedule of assessment, exclusion criteria, and registration with the National Institute of Health (NIH) and other agencies as required using IGC’s cannabis extracted products. Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center, a renowned expert in neuroscience & neurodegeneration, will be the lead on these initiatives. “We believe that cannabis-based compounds can become part of the solution to treat the symptoms of challenging and progressive medical conditions such as Parkinson’s disease and movement disorders. Dr. Barlow and the Parkinson’s Institute and Clinical Center are highly respected in the field and we look forward to working together to bring cannabis-based options to those afflicted by this difficult diagnosis,” stated Ram Mukunda, CEO of IGC. “We feel very fortunate to collaborate with IGC in a rigorous research approach to determine whether holistic cannabis products...

Read More